Validation of the Spotlight 59™ Cancer Panel Applied to IsoFlux Liquid Biopsies

Here we introduce Spotlight 59, an oncology targeted amplification panel designed to leverage the statistical power of replicates and improved bioinformatics to detect mutations present at allele frequencies (AF) down to 0.1% without allowing any false positive calls. The computational method that is included in this workflow, termed ERASE-Seq (Elimination of Recurrent Artifacts and Stochastic Errors) relies on the utilization of a high-fidelity amplicon panel for which the background error rate has been well characterized. Spotlight 59 is a 277-amplicon cancer mutation panel developed in collaboration with Swift Biosciences and tailored to work with the ERASE-Seq approach. It includes 59 genes commonly associated with actionable mutations present in common cancer type.